

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/98280 A2

(51) International Patent Classification⁷: **C07D 243/00**

Maria-Luisa; 1223 Foxglove Lane, West Chester, PA 19388 (US).

(21) International Application Number: PCT/US01/19136

(22) International Filing Date: 15 June 2001 (15.06.2001)

(74) Agents: **PABST, Patrea, L.** et al.; Holland & Knight LLP, One Atlantic Center, Suite 2000, 1201 West Peachtree Street, Atlanta, GA 30309-3400 (US).

(25) Filing Language: English

(81) Designated States (*national*): CA, JP.

(26) Publication Language: English

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(30) Priority Data:
60/212,238 16 June 2000 (16.06.2000) US

(71) Applicant: **ANNOVIS, INC.** [US/US]; 34 Mt. Pleasant Drive, Aston, PA 19014 (US).


Published:
— without international search report and to be republished upon receipt of that report

(72) Inventors: **PEI, Xue-Feng**; 1157 Jarvis Lane, Lansdale, PA 19446 (US). **LI, Baoqing**; 1002 Brassington Drive, Collegeville, PA 19426 (US). **MACCECCHINI,**


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 5H-2,3-BENZODIAZEPINE ANTAGONISTS OF EXCITATORY AMINO ACID RECEPTORS

7- or 8- Mono substituted 5H-2,3-benzodiazepines



X=O, S



X=O, S

(57) **Abstract:** Substituted benzodiazepine compositions are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compounds are generally 7- or 8-mono substituted 5H-2,3-benzodiazepines. The compositions are useful for treating disorders associated with excessive activation of the non-NMDA subtype of the ionotropic EAA receptor. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The compounds are useful therapeutically as sedatives or for the treatment of neurosychopharmacological disorders such as stroke, ischemia and epilepsy. The compositions may be provided in combination with a suitable carrier for oral or parenteral administration. The compounds may be administered orally or parenterally for the treatment of a variety of disorders associated with non-NMDA EAA receptor function.



WO 01/98280 A2

5H-2,3-BENZODIAZEPINE ANTAGONISTS OF EXCITATORY AMINO ACID RECEPTORS

CROSS-REFERENCE TO RELATED APPLICATIONS

5 Priority is claimed to U.S. provisional application Serial No. 60/212,238, filed June 16, 2000.

BACKGROUND OF THE INVENTION

10 This invention relates to mono-substituted 5H-2,3-benzodiazepine compounds useful as antagonists of excitatory amino acid receptors.

 During the past twenty-five years a great deal of attention has been directed toward the excitatory amino acids (EAA's), glutamate and aspartate, since they are believed to be the neurotransmitters responsible for the fast excitatory transmission in the mammalian central nervous system. The
15 ionotropic EAA receptors are generally sub-classified into NMDA and non-NMDA receptors. These classifications are defined by those receptors which preferentially bind N-methyl-D-aspartate (NMDA) and those that are not responsive to NMDA but responsive to α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) or kainic acid (KA).

20 Tarnawa *et al*, describe 2,3-benzodiazepines (*Eur. J. Pharmacol.*, 167:193-199, 1989) which inhibit AMPA stimulated currents in neuronal cells. The 2,3-benzodiazepines such as GYKI 52466 and 53655 described by Tarnawa are non-competitive AMPA antagonists which bind to a novel modulatory site on the AMPA receptor. Meldrum (*Stroke*, 23:861, 1992 &
25 *Brain Res.*, 571:115, 1992) has shown that GYKI 52466 is effective in rat models of both global and focal ischemia. GYKI 52466 was effective in a middle cerebral artery occlusion (MCAO) model of ischemia when given either continuously for 2 hours just after occlusion or delayed for one hour. The compounds reduced cortical infarct volumes by 68% and 48%
30 respectively. In another model of neurodegenerative disease, GYKI 52466 was as effective as the glutamate site competitive antagonist NBQX in rat common carotid arteries model of global ischemia. These two animal

models suggest that these compounds may be useful for the treatment of stroke and neurodegenerative ischemic conditions.

Efforts to find NMDA receptor antagonists and blockers which are neuroprotective have been very successful while efforts to find specific non-
5 NMDA receptor antagonists have been much less successful. A number of pharmaceutical companies have pursued development of ion channel blockers or full antagonists of the NMDA receptor to protect against both chronic and acute neurodegenerative processes. Although some compounds have entered clinical trials, there has been only limited progress in
10 developing a clinically useful NMDA receptor antagonist. Some useful compounds, namely substituted dihydrophthalazines, have been described for use as non-NMDA receptor antagonists (U.S. Patent No. 5,716,956). These compounds are particularly useful because they bind selectively to AMPA receptors. Moreover, 5H-2,3-benzodiazepine AMPA antagonists have been
15 described by Tarnawa, et al. (Amino Acids: Chemistry, Biology and Medicine, Lubec, G., Rosenthal, G.A., Eds.; 1990 p. 538).

It is an object of the invention to provide compounds which are useful as non-NMDA glutamate receptor antagonists as well as methods for their synthesis.

20 It is a further object of the invention to provide non-NMDA receptor antagonists which are useful as sedatives or for the treatment of neuropsychopharmacological disorders such as stroke, ischemia and epilepsy.

It is yet another object of the invention to provide compounds which
25 are useful for the treatment of neurological, neuropsychiatric, neurogenerative and functional disorders associated with excessive activation of the non-NMDA subtypes of the ionotropic EAA receptor.

BRIEF SUMMARY OF THE INVENTION

Compositions are provided which are active as non-NMDA
30 ionotropic excitatory amino acid (EAA) receptor antagonists, in particular, which bind to the AMPA receptors, and which therefore are useful for treating disorders associated with excessive activation of the non-NMDA

subtypes of the ionotropic EAA receptors. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The disclosed compounds are 7- or 8- mono substituted 5*H*-2,3-benzodiazepines.

5 Illustrative compounds include:

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine,

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine,

10 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,

15 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,

1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine,

20 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,

1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,

25 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,

1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine,

30 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,

- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 5 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 10 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 15 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 20 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 25 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 30 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,

- 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 5 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 10 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 15 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 20 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 25 1-(4-Aminophenyl)-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-8-amino-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-4-methyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-7-amino-4-methyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 30 1-(4-Aminophenyl)-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine,

1-(4-Aminophenyl)-8-amino-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine,

1-(4-Aminophenyl)-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine,
and

5 1-(4-Aminophenyl)-7-amino-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine.

The compositions may be provided in combination with a suitable carrier for oral or parenteral administration. The compounds may be administered orally or parenterally for the treatment of a variety of disorders associated with non-NMDA glutamate receptor function. The compositions may be used, for example, as sedatives or for the treatment of neuropsychopharmacological disorders such as stroke, ischemia and epilepsy.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a diagram of the structure of SYM 2267, 1-(4-Aminophenyl)-3-acetyl-3,5-dihydro-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine.

DETAILED DESCRIPTION OF THE INVENTION

I. Glossary of Terms.

The term "**antagonist**" as used herein means any compound which reduces the flow of ions through the non-NMDA receptor.

The term "**neuropsychopharmacological disorder**" as used herein means a disorder resulting from or associated with an excessive flux of ions through the AMPA receptor ligand-gated cation channels, and includes chemical toxicity (including substance tolerance and addiction), excitotoxicity, neurodegenerative disorders (such as Huntington's disease, Parkinson's disease, and Alzheimer's disease), post-stroke sequelae, epilepsy, seizures, mood disorders (such as bipolar disorder, dysthymia, and seasonal affective disorder), and depression. Neurodegenerative disorders can result from dysfunction or malfunction of the AMPA receptor.

30 The term "**NMDA receptor**" as used herein means a receptor which is stimulated, at a minimum, by the excitatory amino acids glutamic acid as

well as by NMDA, but is not stimulated by AMPA or KA. It is a ligand-gated receptor.

5 The term "**AMPA receptor**" as used herein means a receptor which is stimulated, at a minimum, by the excitatory amino acids glutamic acid as well as by AMPA, but is not stimulated by NMDA. It is a ligand-gated receptor.

10 The term "**Kainate receptor**" as used herein means a receptor which is stimulated, at a minimum, by the excitatory amino acids glutamic acid as well as by KA, but is not stimulated by NMDA or AMPA. It is a ligand-gated receptor.


15 The term "**activation**" as used herein in reference to neurotransmitter receptors means the opening of an ion channel to transfer an electric signal generated by an ion flux through the channel. The activation level of receptors can be altered by the disclosed compounds. The term "**excessive activation**" refers to an activation that the opening of an ion channel for a prolonged period of time so that there is an excessive ion flux through the channel, which results in substantial damages to the cell including cell death.

20 Throughout this application when an alkyl substituent is identified, the normal alkyl structure is intended (i.e. butyl is n-butyl) unless otherwise specified. However, when radicals are identified (e.g. R⁵), both branched and straight chains are included in the definition of alkyl, alkenyl, and alkynyl.

II. Compositions With Non-NMDA Receptor Antagonist Properties.

A. Compounds of Formula I

25 Compounds of Formula I are provided which are active as non-NMDA ionotropic EAA receptor antagonists.



where

R^1 , R^2 , R^3 and R^4 are independently

5

H,

HO,

$R^{13}O-$,

halogen (F, Cl, Br),

C1-C3-alkyl,

10

CF_3 ,

$R^{14}CO_2-$,

$R^{14}O_2C-$,

$R^{14}CO-$,

$R^{14}CONH-$,

15

$R^{14}NHCO-$,

$R^{14}NHCO_2-$,

$R^{14}OCONH-$,

$R^{14}O_2S-$,

$R^{14}OS-$, or

20

$R^{15}R^{16}N-$; or

R^1 and R^2 , or R^2 and R^3 , or R^3 and R^4 taken together can be

$-SCH_2S-$,

$-SCH_2O-$,

$-OCH_2S-$,

25

$-SCH_2CH_2S-$,

$-SCH_2CH_2O-$, or

$-OCH_2CH_2S-$;

where one of R^1 , R^2 , R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5 , R^6 , R^7 , and R^8 are independently

H,

5 C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, where the phenyl is substituted

with one or two substituents, C1-C3-alkyl, halogen (F, Cl, Br), $R^{13}O$ -,

10 CF_3 -, $R^{14}O_2S$ -, $R^{14}OS$ -, $R^{14}CO$, $R^{14}CO_2$ -, $R^{14}O_2C$ -, $R^{14}CONH$ -,
 $R^{14}NHCO$; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^7 and R^8 taken together can be C3-C6-cycloalkyl;

R^9 is

15 $R^{15}R^{16}NCO$ -,

$R^{15}R^{16}NCS$ -,

$R^{15}R^{16}N(CR^{17})$ -,

$R^{17}OCO$ -,

$R^{15}CO$ -,

20 $R^{15}R^{16}NCH_2CO$ -,

$R^{14}O_2C-(CH_2)_n$ -,

$R^{15}R^{16}NCO-(CH_2)_n$ -,

$NC-(CH_2)_n$ -,

H,

25 C1-C6-alkyl,

C3-C6-alkenyl, or

C3-C6-cycloalkyl; or

R^8 and R^9 taken together can be

$-(CH_2)_mCH_2(R^{15})NCO$ -,

30 $-(CH_2)_mCH_2OCO$ -, or

$-(CH_2)_mCH_2CH_2CO$ -;

R^{10} and R^{11} are independently

- H,
 $R^{15}R^{16}N-$,
 $R^{15}R^{16}N(CR^{17})-$,
 $R^{14}HNCO-$, or
 $R^{14}CONH-$;
 5 R^{12} is
 H,
 halogen (F, Cl, Br),
 HO,
 10 $R^{13}O-$,
 $R^{15}R^{16}N-$,
 C1-C3-alkyl,
 CF₃,
 $R^{14}CO_2-$,
 15 $R^{14}CO-$, or
 $R^{14}CONH-$;
 R^{13} is C1-C3-alkyl;
 R^{14} is H or C1-C3-alkyl;
 R^{15} and R^{16} are independently
 20 H,
 C1-C10-alkyl,
 C1-C6-perfluoroalkyl,
 C3-C10-alkenyl, or
 C3-C6-cycloalkyl; or
 25 R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;
 R^{17} is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;
 n is 1 to 6;
 m is 0 to 2;
 and pharmaceutically acceptable salts thereof;
 30 where R^{10} and R^{11} cannot be both H.
 Preferred compounds are compounds of Formula I where:

one of four substituents of R^1 , R^2 , R^3 and R^4 must be C1-C3-alkylthio group or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O$ -, $R^{13}S$ -, halogen (F, Cl, Br), or C1-C3-alkyl;

R^2 and R^3 taken together can be $-SCH_2S$ -, $-SCH_2O$ -, or $-OCH_2S$ -;

5 R^9 is

$R^{15}R^{16}NCO$ -,

$R^{15}R^{16}NCS$ -,

$R^{15}R^{16}N(CR^{17})$ -,

$R^{17}OCO$ -,

10 $R^{15}CO$ -, or

H;

R^{10} and R^{11} are independently H, H_2N -, or CH_3CONH -; and pharmaceutically acceptable salts thereof.

Specifically preferred are:

15 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine,

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine,

20 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-amino-8-methoxy-5*H*-2,3-benzodiazepine,

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,

25 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,

30 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine,

1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,


- 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,
- 5 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-10 5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 15 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 20 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 25 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-30 5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,

- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 5 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 10 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine,
- 15 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 20 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 25 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine,
- 30 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, and

1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine.

B. Compounds of Formula II

Compounds of Formula II are provided which are active as non-
5 NMDA ionotropic EAA receptor antagonists.



where

R^1 , R^2 , R^3 and R^4 are independently

- 10 H,
HO,
 $R^{13}O-$,
halogen (F, Cl, Br),
C1-C3-alkyl,
15 CF_3 ,
 $R^{14}CO_2-$,
 $R^{14}O_2C-$,
 $R^{14}CO-$,
 $R^{14}CONH-$,
20 $R^{14}NHCO-$,
 $R^{14}NHCO_2-$,
 $R^{14}OCONH-$,
 $R^{14}O_2S-$,
 $R^{14}OS-$, or
25 $R^{15}R^{16}N-$; or

R^1 and R^2 , or R^2 and R^3 , or R^3 and R^4 taken together can be
-SCH₂S-,
-SCH₂O-,

$-\text{OCH}_2\text{S}-$,
 $-\text{SCH}_2\text{CH}_2\text{S}-$,
 $-\text{SCH}_2\text{CH}_2\text{O}-$, or
 $-\text{OCH}_2\text{CH}_2\text{S}-$; or

5 one of four substituents of R^1 , R^2 , R^3 and R^4 must be C1-C3-alkoxy
 or C1-C3-alkylthio group;

R^5 , R^6 , and R^7 are independently

H,

C1-C6-alkyl,

10 C3-C6-alkenyl,

C3-C6-cycloalkyl, or

phenyl or substituted phenyl, where the phenyl is substituted
 with one or two substituents, C1-C3-alkyl, halogen (F, Cl, Br), $\text{R}^{13}\text{O}-$,
 CF_3- , $\text{R}^{14}\text{O}_2\text{S}-$, $\text{R}^{14}\text{OS}-$, R^{14}CO , $\text{R}^{14}\text{CO}_2-$, $\text{R}^{14}\text{O}_2\text{C}-$, $\text{R}^{14}\text{CONH}-$,

15 R^{14}NHCO ; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

20 H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

25 R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

R^{17} is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

R^{18} and R^{19} are independently

H,

halogen (F, Cl, Br),

30 C1-C3-alkyl,

$\text{R}^{14}\text{O}-$,

CF_3- , or

$R^{14}CO_2^-$;
 R^{20} and R^{21} are independently
 H,
 $R^{15}R^{16}N-$,
 5 $R^{15}HNC(NH)-$, or
 $R^{14}CONH-$;

and pharmaceutically acceptable salts thereof;

where R^{20} and R^{21} cannot both be H.

Preferred compounds are compounds of Formula II where:

10 one of four substituents of R^1 , R^2 , R^3 and R^4 must be C1-C3-alkylthio or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O-$, $R^{13}S-$, halogen (F, Cl, Br), or C1-C3-alkyl;
 R^2 and R^3 taken together can be $-SCH_2S-$, $-SCH_2O-$, or $-OCH_2S-$;
 R^{20} and R^{21} are independently H, H_2N- , or CH_3CONH- ; and
 15 pharmaceutically acceptable salts thereof.

Specifically preferred are:

1-(4-Aminophenyl)-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine,
 1-(4-Aminophenyl)-8-amino-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine,
 1-(4-Aminophenyl)-4-methyl-8-methoxy-5*H*-2,3-benzodiazepine,
 20 1-(4-Aminophenyl)-7-amino-4-methyl-8-methoxy-5*H*-2,3-benzodiazepine,
 1-(4-Aminophenyl)-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine,
 1-(4-Aminophenyl)-8-amino-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine,
 1-(4-Aminophenyl)-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine, and
 1-(4-Aminophenyl)-7-amino-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine.

25 The compounds of Formulas I and II may be combined with a suitable pharmaceutical carrier and used to treat neurological, neuropsychological, neuropsychiatric, neurodegenerative, neuropsychopharmacological and functional disorders associated with excessive activation of the non-NMDA subtype of the ionotropic EAA
 30 receptors. The compounds can also be used as testing agents to identify and characterize other compounds for the treatment of acute and chronic

neurodegenerative diseases, seizures, depression, anxiety and substance addiction.

Pharmaceutically acceptable salts include both the metallic (inorganic) salts and organic salts; a list of which is given in Remington's
5 Pharmaceutical Sciences 17th Edition, p. 1418 (1985). It is well known to one skilled in the art that an appropriate salt form is chosen based on physical and chemical stability, flowability, hygroscopicity and solubility.

III. Synthesis


The compounds of Formula I or II may be prepared using synthetic
10 reactions and techniques available in the art, as described, for example in March, "Advanced Organic Chemistry," 4th Edition, 1992, Wiley-Interscience Publication, New York. The reactions are performed in solvents suitable to the reagents and materials employed and suitable for the transformation being effected. Depending upon the synthetic route selected,
15 and the functionality of the starting material or intermediates, the appropriate protection groups and deprotection conditions available in the art of organic synthesis may be utilized in the synthesis of the compound.

In one embodiment, compounds of Formula I and II may be synthesized as outlined in Schemes 1-3.

20 Compounds with 7-alkoxy or 7-alkylthio substituents may be synthesized as outlined in Scheme 1.

Ketone **1** gave alcohols **2** by reduction with sodium borohydride in a solvent such as methanol at a temperature of 0° to 30°C for 1-8 hours. Acid-catalyzed reaction of **2** with 4-nitrobenzaldehydes led to **3**, which was
25 oxidized by air in DMF/DMSO to semiketal **4**. Reaction of semiketal **4** with acetic hydrazide in refluxing ethanol gave hydrazones **5**. Treatment of **5** with methanesulfonyl chloride and triethylamine gave mesylates **6**. The mesylates **6** were treated with lithium tert-butoxide in THF to give cyclized product **7**. The nitro groups of **7** were reduced by catalytic hydrogenation
30 to give desired product **8**.

Scheme 1



Reaction conditions: (a) $NaBH_4$, MeOH, $0^\circ C$; (b) HCl in dioxane, reflux; (c) air, DMF/DMSO, $-5^\circ C$; (d) H_2NNHAc /EtOH, catalytic HCl, reflux; (e) $MsCl$ /Et₃N/DCM, $-5^\circ C$; (f) $t-BuOLi$ /THF, $0^\circ C$; (g) H_2 , Pd/C, EtOAc.


Compounds with 8-alkoxy or 8-alkylthio substituents may be synthesized as outlined in Scheme 2.

Nitration of compound 9 gave compound 10. The nitro groups of 10 were reduced by catalytic hydrogenation to give aniline 11, which was converted to amide 12, by reaction with acetic anhydride. Ketone 12 gave alcohols 13 by reduction with sodium borohydride in a solvent such as methanol at a temperature of 0° to $30^\circ C$ for 1-8 hours. Acid-catalyzed reaction of 13 with 4-nitrobenzaldehydes led to 14, which were deprotected, with 4N H_2SO_4 in methanol to give aniline 15. The amine group in 15 was removed by first converting to diazonium, then decomposing the diazonium with H_3PO_2 to give compound 16. Compound 16 was oxidized by air in DMF/DMSO to semiketal 17. Reaction of semiketal 17 with acetic

hydrazide in refluxing ethanol gave hydrazones **18**. Treatment of **18** with methanesulfonyl chloride and triethylamine gave mesylates **19**. The mesylates **19** were treated with lithium tert-butoxide in THF to give cyclized product **20**. The nitro groups of **20** were reduced by catalytic

5 hydrogenation to give desired product **21**.

Scheme 2




Compounds with 8-alkoxy or 8-alkylthio and 7-amino substituents may be synthesized as outlined in Scheme 3.

- 5 Compound 14 was oxidized by air in DMF/DMSO to semiketal 22. Reaction of semiketal 22 with acetic hydrazide in refluxing ethanol gave hydrazones 23. Treatment of 23 with methanesulfonyl chloride and triethylamine gave mesylates 24. The mesylates 24 were treated with lithium *tert*-butoxide in THF to give cyclized product 25. Amide 25 was hydrolyzed
- 10 to give aniline 26, which was reduced by catalytic hydrogenation to give

desired product 27. Compound 14 was oxidized to diketone 28, which was treated with hydrazine with concomitant *N*-deacetylation to give benzodiazepine 29.

Scheme 3



5

IV. *In Vitro* And *In Vivo* Assays Of Activity And Therapeutic Efficacy

In vivo and *in vitro* assays may be conducted to determine the activity of the compounds as antagonists of the non-NMDA receptors, *i.e.*, the ionotropic EAA receptors which bind AMPA or KA. In combination, *in vitro* and *in vivo* assays are predictive of the activity of these compounds for

10

treatment of patients. This is supported, for example, by numerous studies in the literature illustrating that *in vitro* and *in vivo* studies of NMDA receptor modulation by a test compound provide a good indication of the compound's efficacy in treating disorders associated with excessive activation of the NMDA receptor. See, for example: Meldrum, *Epilepsy Research*, 12:189-196 (1992); Lipton and Rosenberg, *New England Journal of Medicine*, 330:613-622 (1994); and McBurney, *Neurobiology of Aging*, 15:271-273 (1994).

A. Electrophysiology

The potency of the disclosed compounds for drug inhibition of the AMPA receptor can be tested using the whole-cell patch clamp technique on primary cultures of rat neocortex. The general procedure for stimulating AMPA-receptor mediated currents with KA and for the measurement of current inhibition is based on that used by Donevan and Rogawski (*Neuron*, 10: 51-59, 1993) for 2,3-benzodiazepines.

Standard extracellular bath solutions and intracellular pipette solutions are used as described in detail by Hussy and coworkers (*J. Physiol. (Lond.)*, 481.2: 311-323, 1994). The drug application system is designed to allow rapid switching between 7 different reservoirs containing either control bath solution, kainic acid (50 μ M), or kainic acid (50 μ M) plus antagonist (10 μ M). Each recording is begun with a control response to KA alone.

Following the establishment of a 2-3 sec duration steady baseline, bathing solution is switched to one containing KA plus antagonist for an additional 2-3 sec period. Alternatively, 5 different doses of a single compound are tested for the determination of the antagonist IC₅₀.

B. Neurodegenerative Transient Global Forebrain Ischemia

The extent of protection by a test compound in a model of brain ischemia may be assayed as described by Meldrum *et al.* (*Brain Res.*, 571:115, 1992), and references cited therein. Male Wistar rats (250-300 g) are anesthetized using halothane-oxygen-nitrogen mixture and both vertebral arteries are permanently occluded by electrocauterisation within the alar foraminae of the first cervical vertebra. At the same time, both common

carotid arteries are isolated and atraumatic clamps placed around each one. One femoral vein is cannulated to enable the subsequent iv administration of fluid. The following day cerebral ischemia is induced in the unanaesthetised animal, by tightening the clamps around the carotid arteries for 20 min.

- 5 Carotid clamping results. Body temperature is maintained at 37°C by use of a rectal probe and hot plate. Seven days after the ischemic insult rats are sacrificed and the brains processed for light microscopy. Neuroprotection is assessed by examination of the extent of damage in the cortex and hippocampus. Compounds may be selected which are active in this model.

10 **C. Neurodegenerative Permanent Focal Ischemia**

- The extent of protection by a test compound in a model of brain ischemia may be tested using a model described by Meldrum and Smith (*Stroke*, 23:861, 1992), and references cited therein. Male Fisher F344 rats (210-310 g) are anesthetized with halothane-oxygen-nitrogen mixture receive
15 a small incision between the eye and ear, the mandibular muscles are retracted to expose the orbit and zygomatic arch. A small craniotomy is made to expose the base of the middle cerebral artery. Bipolar coagulation is used to permanently occlude the artery at the base. One day after the ischemic insult rats are sacrificed and the brains processed for light
20 microscopic examination. Lesion volume is determined by using Cavalarei's principle. Compounds may be selected which are active in this model.

D. Maximum Electro Shock (MES) Seizure Test

- The extent of protection by a test compound in a seizure model is tested as described by Rogawski *et al.* (*Epilepsy Research*, 15:179-184, 1993). Male NIH Swiss mice (25-30 g) are injected ip with the test drug.
25 The mice are subjected to a 0.2 sec, 60 Hz, 50 mA electrical stimulus delivered with corneal electrodes wetted with 0.9% saline at 15-30 min post dosing. Animals failing to show tonic hind limb extension are scored as protected. Compounds may be selected which are active in this model.

30 **E. Subcutaneous Metrazol (scMET) Seizure Test**

This test can be used to determine the extent of protection by a test compound in a seizure model. The method used is that of Chen *et al.* (*Proc.*

Soc. Exp. Biol. Med., 87:334, 1954). Mice are randomly assigned to vehicle or treatment groups of 3-10 animals per group and then dosed accordingly. Metrazol (pentylenetetrazol) 90 mg/kg is administered subcutaneously (sc) at different time points (0.25, 0.5, 1, 2, 4 hr) after the treatment or control groups . The mice individually housed in clear runs and observed for the presence or absence of clonic seizure activity (>5 s duration) for 30 min after metrazol dosing. A compound is considered active if no seizure is observed. Data is analyzed using a quantal measure (protection/number tested).

V. Dosage Forms

The disclosed compounds can be administered parenterally, that is, subcutaneously, intramuscularly, or intravenously and, alternatively, administered orally, in a dose range of between about 0.01 and 100 mg/kg body weight.

The active ingredient can be administered parenterally in sterile liquid dosage forms. In general, water, a suitable oil, saline, aqueous dextrose, and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble form of the active ingredient, suitable stabilizing agents, and, if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid either alone or combined are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.

The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. The active ingredients also may be

provided in a particle for sustained or pulsed delivery such as a liposome or microcapsule. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, a standard reference text in this field.

Optionally, the compounds either alone or in combination with a carrier may be administered by implantation or by application to a mucosal surface, for example, the nasal-pharyngeal region and/or lungs using an aerosol or may be administered to a skin surface via a topical carrier such as a cream or lotion.

The compounds of this invention and their preparation can be understood further by the following non-limiting examples which describe the synthesis of exemplary compounds. In these examples, unless otherwise indicated, all temperatures are in degrees Celsius and parts and percentages are by weight.

Examples

The following examples show the synthesis of compounds 2 through 8 as shown in Scheme 1.

Example 1: Synthesis of 1-(3-Methoxyphenyl)-2-propyl alcohol (2). To a solution of 3-methoxyphenylacetone (1, 1.0 g) in methanol (30 ml) was added NaBH₄ (360 mg) in portions in the period of 20 min at 0 °C. The resulting solution was stirred at such temperature for another 40 min. No more starting materials were detected from TLC. Ice water was added to the reaction slowly. It was extracted with CHCl₃ three times. The combined organic phase was washed with brine, and dried over Na₂SO₄. Removal of the solvent afforded the crude product. Purification of the crude product by using a silica gel column gave the desired product 2 (1.01 g, 100%).

Example 2: Synthesis of 3-Methyl-1-(4-nitrophenyl)-6-methoxyisochroman (3). To a solution of 1-(3'-methoxyphenyl)-2-propyl

alcohol **2** (0.98g, 5.8 mmol) in 25 ml of HCl solution in 1,4-dioxane was added 4-nitrobenzaldehyde (0.91g, 6.0 mmol) in one portion. The solution was refluxed for 4 hours. After removing the solvent under reduced pressure, the residue was washed with cold ethanol three times, affording the product **3** (1.62g, yield 90 %). ¹HNMR(CDCl₃): 8.20 (d, J=8.7 Hz, 2H), 7.50 (d, J=8.7 Hz, 2H), 6.65-6.48 (m, 3H), 5.78 (s, 1H), 4.01 (m, 1H), 3.76 (s, 3H), 2.80 (m, 2H), 1.40 (d, J=6.1 Hz).

Example 3: Synthesis of 1-Hydroxy-3-methyl-1-(4-nitrophenyl)-6-methoxyisochroman (4). A solution of **3** (1.3 g) in 4 ml of DMSO and 24 ml of DMF was cooled to 8-12 °C and air was passed through the mixture. To the solution was added 1.2 ml of 50% aqueous sodium hydroxide in one portion and the resulting mixture was stirred for 5 hours. HCl (1 N) was added, and extracted with ethyl acetate three times. The combined organic phase was washed with water in order to remove DMF, dried over Na₂SO₄. Removal of the solvent afforded syrup crude product (1.6 g), which was used directly for the next step.

Example 4: Synthesis of 6'-(2-Hydroxypropyl)-4'-methoxy-4-nitrobenzophenone acetylhydrazone (5). To a solution of **4** (1.6 g) in 25 ml of ethanol was added acetic hydrazide (0.4 g) and 2 drops of concentrated HCl. The resulting solution was heated to reflux for 3 hours. The solvent was removed under reduced pressure. The residue was treated with NaHCO₃, and extracted with ethyl acetate. The combined organic phase was washed with brine, dried over Na₂SO₄. Removal of the solvent gave the desired product (1.25 g).

Example 5: Synthesis of 6'-(2-Methanesulfonyloxypropyl)-4'-methoxy-4-nitrobenzophenone acetylhydrazone (6). To a solution of **5** (0.57 g) in 20 ml of CH₂Cl₂ was added 0.75 ml of triethyl amine, 0.32 ml of methanesulfonyl chloride at 0-10 °C. After 30 min, no more starting material was detected from TLC. Water was added, extracted with CH₂Cl₂. The organic phase was washed with HCl (1N), brine, dried over Na₂SO₄. Removal of the solvent afforded product **6** (0.61 g).

Example 6: Synthesis of 3-Acetyl-3,5-dihydro-4-methyl-7-methoxy-1-(4-nitrophenyl)-5H-2,3-benzodiazepine (7). To a solution of the mesylate **6** (0.56 g) in 10 ml of THF was added lithium *tert*-butoxide (2.3 ml, 1M) at 0 °C. The mixture was warmed to room temperature and stirred
5 for 4 hours. The reaction was quenched by adding a saturated NH₄Cl solution. The mixture was diluted with ethyl acetate and washed with water and brine. The organic phase was dried over Na₂SO₄. Removal of the solvent gave the crude product. Purification of the crude product by silica afforded the desired product **7** (0.36g.) ¹HNMR (CDCl₃): 8.25 (d, J=9.0 Hz,
10 2H), 7.73 (d, J=9.0, 2H), 7.00-6.75 (m, 3H), 5.45 (m, 1H), 3.88 (s, 3H), 3.15-2.83 (m, 2H), 2.32 (s, 3H), 1.05 (d, J=6.6 Hz, 3H).

Example 7: Synthesis of 1-(4-Aminophenyl)-3-acetyl-3,5-dihydro-4-methyl-7-methoxy-5H-2,3-benzodiazepine (8). The mixture of **7** (0.32 g, 0.91 mmol) and 10% palladium on carbon (0.2 g), and ethanol (25
15 ml) was stirred under hydrogen for 1.5 hours. Filtration of the catalyst and evaporation of solvent gave desired product **8** (0.27 g, yield, 92%) as yellow solid. ¹HNMR(CDCl₃): 7.50 (d, J=9.0 Hz, 2H), 7.0 (m, 1H), 6.80 (m, 2H),
6.69 (d, J=9.0Hz, 2H), 5.26(m, 1H), 4.0 (br, 2H), 3.83 (s, 3H), 2.70 (m, 2H),
2.0 (s, 3H), 1.32 (d, J=6.4 Hz, 3H).

20 The following examples show the synthesis of compounds 10 through 21 as shown in Scheme 2.

Example 8: Synthesis of 4-Methoxy-3-nitrophenylacetone (10). To a solution of 4-methoxyphenylacetone **9** (6.56 g, 4 mmol) in acetic anhydride (16 mmol) was added 90 % HNO₃ dropwise at -5°C. After adding
25 HNO₃, the ice-bath was removed and allowed to warm up to room temperature. The reaction was quenched by adding ice water. The resulting solution was extracted with ethyl acetate three times. The organic phase was dried over Na₂SO₄. Removal of the solvent under reduced pressure afforded crude product. Purification of the crude product by using silica gel column
30 gave **10** (4.9 g, 59%). ¹HNMR(CDCl₃): 7.70 (d, J=2.1 Hz, 1H), 7.37 (dd, J=2.2 Hz, 8.5 Hz, 1H), 7.08 (d, J=8.5 Hz, 1H), 3.95 (s, 3H), 3.74 (s, 2H),
2.21 (s, 3 H).

Example 9: Synthesis of 3-Amino-4-methoxyphenylacetone (11).

The mixture of compound **10** (3.0 g, 14.3 mmol) and 10 % palladium on carbon (1.6 g) in ethanol (230 ml) was stirred under hydrogen for 3 hours. Filtration of the catalyst and evaporation of solvent gave desired product **11** (2.41 g, 94 %).

Example 10: Synthesis of 3-Acetylamino-4-methoxyphenylacetone (12).

To the mixture of compound **11** (0.25 g, 1.39 mmol) in chloroform (30 ml) was added acetic anhydride (1.2 ml) and catalytic amount of DMAP (10 mg) at 0 °C. After stirring at such temperature for 3 hours, no more starting materials were detected on TLC. The reaction was quenched by adding ice water, extracted with CH₂Cl₂ twice. The organic layer was washed with brine, dried over Na₂SO₄. Removal of the solvent afforded the crude product. Purification of the crude product by using silica gel column gave 0.3 g (97%) of desired product **12**.
¹HNMR(CDCl₃): 8.25 (d, J=1.2 Hz, 1H), 7.79 (br, 1H), 6.81 (m, 2H), 3.86 (s, 3H), 3.64 (s, 2H), 2.20 (s, 3H), 1.95 (s, 3H).

Example 11: Synthesis of 1-(3-Acetylamino-4-methoxyphenyl)-2-propyl alcohol (13).

To a solution of compound **12** (0.25 g, 1.13 mmol) in methanol was added NaBH₄ in portions in the period of 20 min at 0 °C. The resulting solution was stirred at such temperature for another 40 min. No more starting materials were detected on TLC. Ice water was added to the reaction slowly. It was extracted with CHCl₃ three times. The combined organic phases were washed with brine, and dried over Na₂SO₄. Removal of the solvent afforded the crude product. Purification of the crude product by using a silica gel column gave the desired product **13** (0.24 g, 95%).
¹HNMR(CDCl₃): 8.24 (d, J=1.8 Hz, 1H), 7.75 (br, 1H), 6.82 (m, 2H), 4.00 (m, 1H), 3.86 (s, 3H), 2.70 (m, 2H), 2.20 (s, 3H), 1.24 (d, J=6.1 Hz, 3H).

Example 12: Synthesis of 6-Acetylamino-3-methyl-1-(4-nitrophenyl)-7-methoxyisochroman (14).

To a solution of compound **13** (0.23g, 1.03 mmol) in 15 ml of HCl solution in 1,4-dioxane was added 4-nitrobenzaldehyde (0.16 g, 1.06 mmol) in one portion. After refluxing for 5 hours, the solvent was removed under reduced pressure. The residue was

washed with cold ethanol three times, and dried to give the product **14** (0.21g, 66%).

Example 13: Synthesis of 6-Amino-3-methyl-1-(4-nitrophenyl)-7-methoxyisochroman (15). Solution of **14** (0.114 g, 0.32 mmol) in 5 ml of 4N H₂SO₄ and 5 ml of methanol was heated to reflux. After refluxing for 15 hours, the methanol was removed under reduced pressure. The remaining aqueous solution was neutralized with NaHCO₃ to pH 9, followed by extraction with ethyl acetate three times. The combined organic phase was dried over Na₂SO₄. Removal of the solvent afforded the desired product **15** (100 mg, 100%) which was used directly for next step.

Example 14: Synthesis of 3-Methyl-1-(4-nitrophenyl)-7-methoxyisochroman (16). Solution of **15** (100 mg, 0.32 mmol) in 5 ml of 4N H₂SO₄ was treated with NaNO₂ (29.6 mg, 1.16 eq) at 0 °C for 15 min, followed by adding H₃PO₂ (50 %, 0.25 ml) at such temperature. After refluxing for 5 hours, the solution was extracted with ethyl acetate three times. The combined organic phases were dried over Na₂SO₄. Removal of the solvent afforded the crude product. Purification of the crude product by using silica gel column gave the desired product **16** (82 mg, 86%).

Example 15: Synthesis of 1-Hydroxy-3-methyl-1-(4-nitrophenyl)-7-methoxyisochroman (17). A solution of **16** (1.3 g) in 4 ml of DMSO and 24 ml of DMF was cooled to 8-12 °C and air was passed through the mixture. To the solution was added 1.2 ml of 50 % aqueous sodium hydroxide in one portion and the resulting mixture was stirred for 5 hours. HCl (1 N) was added, and extracted with ethyl acetate three times. The combined organic phases were washed with water, dried over Na₂SO₄. Removal of the solvent afforded **17** as a syrup (1.6 g), which was used directly for the next step.

Example 16: Synthesis of 6'-(2-Hydroxypropyl)-3'-methoxy-4-nitrobenzophenone acetylhydrazone (18). To a solution of **17** (1.8 g) in 25 ml of ethanol was added acetic hydrazide (0.5 g) and 2 drops of concentrated HCl. The resulting solution was heated to reflux for 3 hours. The solvent was removed under reduced pressure. The residue was treated

with NaHCO₃, and extracted with ethyl acetate. The combined organic phase was washed with brine, dried over Na₂SO₄. Removal of the solvent gave the desired product **18** (1.32 g).

Example 17: Synthesis of 6'-(2-Methanesulfonyloxypropyl)-3'-methoxy-4-nitrobenzophenone acetylhydrazone (19). To a solution of **18** (1.12 g, 3 mmol) in 20 ml of CH₂Cl₂ was added 1.5 ml of triethyl amine, 0.60 ml of methanesulfonyl chloride at 0-10 °C. After 30 min, no more starting material was detected on TLC. Water was added, extracted with CH₂Cl₂. The organic phase was washed with HCl (1N), brine, dried over Na₂SO₄. Removal of the solvent afforded product **19** (1.20 g, 89%).

Example 18: Synthesis of 3-Acetyl-3,5-dihydro-4-methyl-8-methoxy-1-(4-nitrophenyl)-5H-2,3-benzodiazepine (20). To a solution of the mesylate **19** (1.5 g,) in 80 ml of THF was added lithium *tert*-butoxide (16.5 ml, 1M) at 0 °C. The mixture was warmed to room temperature and stirred for 4 hours. The reaction was quenched by adding a saturated NH₄Cl solution. The mixture was diluted with ethyl acetate and washed with water and brine. The organic phase was dried over Na₂SO₄. Removal of the solvent gave the crude product. Purification of the crude product by silica afforded the desired product **20** (0.97g). ¹HNMR(CDCl₃): 8.26 (d, J=9.0 Hz, 2H), 7.75 (d, J=9.0 Hz, 2H), 7.20 (d, J=9.0 Hz, 1H), 6.93 (dd, J=9.0 Hz, 2.1 Hz, 1H), 6.58 (d, J=2.1 Hz, 1H), 5.40 (m, 1H), 3.72 (s, 3H), 3.10-2.80 (m, 2H), 2.36 (s, 3H), 1.00 (d, J=6.0 Hz, 3H).

Example 19: Synthesis of 1-(4-Aminophenyl)-3-acetyl-3,5-dihydro-4-methyl-8-methoxy-5H-2,3-benzodiazepine (21). The mixture of **20** (0.72 g, 0.91 mmol) and 10 % palladium on carbon (0.25 g), and ethyl acetate (40 ml) was stirred under hydrogen for 1.5 hours. Filtration of the catalyst and purification by silica gel gave desired product **21** (0.27 g, 46%) as yellow solid. ¹HNMR(CDCl₃): 7.76(d, J=9.0Hz, 2H), 7.20 (d, J=7.2 Hz, 1H), 7.0 (d, J=9.0, 2H), 6.86 (d, J=7.2 Hz, 1H), 6.60 (s, 1H), 5.38 (br, 2H), 5.20 (m, 1H), 3.73 (s, 3H), 2.85-2.63 (m, 2H), 2.07 (s, 3H), 1.28 (d, J=6.0 Hz, 3H).

The following examples show the synthesis of compounds 22 through 29 as shown in Scheme 3.

Example 20: Synthesis of 6-Acetylamino-1-hydroxy-3-methyl-1-(4-nitrophenyl)-7-methoxyisochroman (22). A solution of 14 (1.8 g) in 5 ml of DMSO and 30 ml of DMF was cooled to 8-12 °C and air was passed through the mixture. To the solution was added 1.2 ml of 50% aqueous sodium hydroxide in one portion and the resulting mixture was stirred for 5 hours. HCl (1 N) was added, and extracted with ethyl acetate three times. The combined organic phase was washed with water, dried over Na₂SO₄. Removal of the solvent afforded 22 (1.9 g) as a syrup, which was used directly for the next step.

Example 21: Synthesis of 2'-Acetylamino-6'-(2-hydroxypropyl)-3'-methoxy-4-nitrobenzophenone acetylhydrazone (23). To a solution of 22 (1.7 g) in 25 ml of ethanol was added acetic hydrazide (0.5 g) and 2 drops of concentrated HCl. The resulting solution was refluxed for 3 hours. The solvent was removed under reduced pressure. The residue was treated with NaHCO₃, and extracted with ethyl acetate. The combined organic phases were washed with brine, dried over Na₂SO₄. Removal of the solvent gave the desired product 23 (1.25 g).

Example 22: Synthesis of 2'-Acetylamino-6'-(2-methanesulfonyloxypropyl)-3'-methoxy-4-nitrobenzophenone acetylhydrazone (24). To a solution of 23 (1.1 g) in 20 ml of CH₂Cl₂ was added 1.5 ml of triethyl amine, 0.60 ml of methanesulfonyl chloride at 0-10 °C. After 30 min, no more starting material was detected on TLC. Water was added, extracted with CH₂Cl₂. The organic phase was washed with HCl (1N), brine, dried over Na₂SO₄. Removal of the solvent afforded product 24 (1.21 g).

Example 23: Synthesis of 3-Acetyl-7-acetylamino-3,5-dihydro-4-methyl-8-methoxy-1-(4-nitrophenyl)-5H-2,3-benzodiazepine (25). To a solution of the mesylate 23 (1.15 g, 2.27 mmol) in 15 ml of THF was added lithium *tert*-butoxide (4.5 ml, 1M) at 0 °C. The mixture was warmed to room temperature and stirred for 4 hours. Adding a saturated NH₄Cl solution

quenched the reaction. The mixture was diluted with ethyl acetate and washed with water and brine. The organic phase was dried over Na₂SO₄. Removal of the solvent gave the crude product. Purification of the crude product by silica afforded the desired product **25** (0.86g, 92%).

5 **Example 24: Synthesis of 3-Acetyl-7-amino-3.5-dihydro-4-methyl-8-methoxy-1-(4-nitrophenyl)-5H-2,3-benzodiazepine (26).** The solution of acetyl amide **25** (0.8 g, 1.95 mmol) in 20 ml of methanol and 10 ml of NaOH (2 N) was refluxed until there is no more starting material left on TLC. The solution was diluted with water, and extracted with CH₂Cl₂
10 three times. Removal of the solvent afforded the crude product, which was purified by using a silica gel column to give the desired product **26** (0.56 g, 78%). ¹HNMR(CDCl₃): 8.25 (d, J=9.0 Hz, 2H), 7.73 (d, J=9.0 Hz, 2H), 7.48 (s, 1H), 7.02 (s, 1H), 6.55 (s, 1H), 5.40 (m, 1H), 3.70 (s, 3H), 3.08 (m, 2H), 2.46 (s, 3H), 1.02 (d, J=6.4 Hz, 3H).

15 **Example 25: Synthesis of 1-(4-Aminophenyl)-3-acetyl-7-amino-3.5-dihydro-4-methyl-8-methoxy-5H-2,3-benzodiazepine (27).** The mixture of compound **26** (0.50 g, 1.36 mmol) and 10% palladium on carbon (0.2 g), and ethanol (20 ml) was stirred under hydrogen for 3.5 hours. Filtration of the catalyst and evaporation of solvent gave desired product **27**
20 (0.30 g, 65%) as yellow solid. ¹HNMR(CDCl₃): 7.62 (d, J=8.4 Hz, 2H), 7.49 (s, 1H), 7.10 (br, 2H), 6.83 (d, J=8.4 Hz, 2H), 6.69 (s, 1H), 5.20 (m, 1H), 3.78 (s, 3H), 3.10 (s, 2H), 2.70 (m, 2H), 2.08 (s, 3H), 1.20 (d, J=6.4 Hz, 3H).

Example 26: Synthesis of 3-Acetylamino-4-methoxy-6-(4-nitrobenzoyl)-phenylacetone (28). To a solution of compound **14** (0.375g, 1.05 mmol) in 30 ml of acetone was added 3 ml of CrO₃ in 35% H₂SO₄ at 0
25 °C. The resulted solution was stirred another 2 h at same temperature. Ice water was added. The solution was extracted with ethyl acetate three times. The combined organic phase was washed with brine, followed by drying over Na₂SO₄. Removal of the solvent afforded the desired product in the
30 yield of 82%. ¹HNMR(CDCl₃): 8.5-7.8 (m, 6H), 6.8 (s, 1H), 4.08 (s, 2H), 3.8 (s, 3H), 2.24 (s, 3H), 2.21 (s, 3H).

Example 27: Synthesis of 7-Amino-4-methyl-8-methoxy-1-(4-nitrophenyl)-5H-2,3-benzodiazepine (29). The solution of **25** (0.3 g, 0.81 mmol) in 30 ml of ethanol and 1.0 ml of $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ was refluxing until there is no more starting material left from TLC. The solution was diluted with water, and extracted with DCM three times. Removal of the solvent afforded the crude product, which was purified by using a silica gel column, gave the desired 0.17g in the yield of 65%. ^1H NMR(CDCl_3): 8.9 (s, 1H), 8.4 (d, 2H), 8.17 (br, 1H), 7.9 (d, 2H), 7.55 (br, 1H), 7.1 (s, 1H), 3.9 (s, 3H), 2.3 (s, 3H).

Example 28: *In Vitro* And *In Vivo* Tests for Inhibition of Ca^{2+} Influx into Cortical Cells Stimulated with AMPA

Three of the antagonists disclosed herein were tested, *in vitro*, for inhibition of Ca^{2+} influx into cortical cells stimulated with AMPA. They are 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5H-2,3-benzodiazepine (**8**) (SYM 2267), 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5H-2,3-benzodiazepine (**21**) (SYM 2268), and 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-amino-8-methoxy-5H-2,3-benzodiazepine (**27**) (SYM 2269), respectively. The *in vitro* test measures inhibition of Ca^{2+} influx into cortical cells stimulated with 50 M AMPA by the test compounds. The rationale underlying this assay is that stimulation of the cortical cells with AMPA activates AMPA receptors causing Ca^{2+} influx with an increase in intracellular Ca^{2+} which is then detected by measuring an increase in fluorescence. The Ca^{2+} increase comes mostly from extracellular (influx of Ca^{2+} through the channel into the cell), but could also come from intracellular sources (release of Ca^{2+} from storage). The inhibition of the AMPA receptor function is detected by a decrease in the level of intracellular Ca^{2+} and a decrease in fluorescence. The results are summarized in Table 1.

Table 1. Inhibition of Ca^{2+} Influx into Cortical Cells with 50 μM AMPA

Compound	IC_{50} (μM)
SYM 2267	26.1
SYM 2268	16.6
SYM 2269	7.3

Of the three compounds tested, SYM 2269 ($\text{IC}_{50} = 7.3 \mu\text{M}$) is the most potent one for inhibiting AMPA receptor function on cortical neurons in culture. SYM 2267 was evaluated for *in vivo* anticonvulsant activity in the maximal electro shock (MES) model in rats. The rats were given the compound orally (PO) and were found to be fully protected from the MES seizures at 30 mg/kg. No sedative or toxic side effects were observed in the rotorod test. Further tests indicated that SYM 2267 has a MES effective dosage of 8.4 mg/kg ($\text{ED}_{50} = 8.4 \text{ mg/kg}$).

It is understood that the disclosed invention is not limited to the particular methodology, protocols, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.


It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "the compound" is a reference to one or more compounds and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are as described. Nothing herein is to be construed as an

admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

We claim:

1. A compound of Formula I:



wherein

R^1 , R^2 , R^3 and R^4 are independently

H,

HO,

$R^{13}O-$,

halogen (F, Cl, Br),

C1-C3-alkyl,

CF_3 ,

$R^{14}CO_2-$,

$R^{14}O_2C-$,

$R^{14}CO-$,

$R^{14}CONH-$,

$R^{14}NHCO-$,

$R^{14}NHCO_2-$,

$R^{14}OCONH-$,

$R^{14}O_2S-$,

$R^{14}OS-$, or

$R^{15}R^{16}N-$; or

R^1 and R^2 , or R^2 and R^3 , or R^3 and R^4 taken together can be

$-SCH_2S-$,

$-SCH_2O-$,

$-\text{OCH}_2\text{S}-$,
 $-\text{SCH}_2\text{CH}_2\text{S}-$,
 $-\text{SCH}_2\text{CH}_2\text{O}-$, or
 $-\text{OCH}_2\text{CH}_2\text{S}-$;

wherein one of R^1 , R^2 , R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5 , R^6 , R^7 , and R^8 are independently

H ,
 C1-C6-alkyl,
 C3-C6-alkenyl,
 C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen (F, Cl, Br), $\text{R}^{13}\text{O}-$, CF_3- , $\text{R}^{14}\text{O}_2\text{S}-$, $\text{R}^{14}\text{OS}-$, R^{14}CO , $\text{R}^{14}\text{CO}_2-$, $\text{R}^{14}\text{O}_2\text{C}-$, $\text{R}^{14}\text{CONH}-$, R^{14}NHCO ; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^7 and R^8 taken together can be C3-C6-cycloalkyl;

R^9 is

$\text{R}^{15}\text{R}^{16}\text{NCO}-$,
 $\text{R}^{15}\text{R}^{16}\text{NCS}-$,
 $\text{R}^{15}\text{R}^{16}\text{N}(\text{CR}^{17})-$,
 $\text{R}^{17}\text{OCO}-$,
 $\text{R}^{15}\text{CO}-$,
 $\text{R}^{15}\text{R}^{16}\text{NCH}_2\text{CO}-$,
 $\text{R}^{14}\text{O}_2\text{C}-(\text{CH}_2)_n-$,
 $\text{R}^{15}\text{R}^{16}\text{NCO}-(\text{CH}_2)_n-$,
 $\text{NC}-(\text{CH}_2)_n-$,
 H ,
 C1-C6-alkyl,
 C3-C6-alkenyl, or
 C3-C6-cycloalkyl; or

R^8 and R^9 taken together can be

$$-(\text{CH}_2)_m\text{CH}_2(\text{R}^{15})\text{NCO}-,$$

$$-(\text{CH}_2)_m\text{CH}_2\text{OCO}-, \text{ or}$$

$$-(\text{CH}_2)_m\text{CH}_2\text{CH}_2\text{CO}-;$$

$$\text{R}^{10} \text{ and } \text{R}^{11} \text{ are independently}$$

$$\text{H},$$

$$\text{R}^{15}\text{R}^{16}\text{N}-,$$

$$\text{R}^{15}\text{R}^{16}\text{N}(\text{CR}^{17})-,$$

$$\text{R}^{14}\text{HNCO}-, \text{ or}$$

$$\text{R}^{14}\text{CONH}-;$$

$$\text{R}^{12} \text{ is}$$

$$\text{H},$$

$$\text{halogen (F, Cl, Br),}$$

$$\text{HO},$$

$$\text{R}^{13}\text{O}-,$$

$$\text{R}^{15}\text{R}^{16}\text{N}-,$$

$$\text{C1-C3-alkyl},$$

$$\text{CF}_3,$$

$$\text{R}^{14}\text{CO}_2-,$$

$$\text{R}^{14}\text{CO}-, \text{ or}$$

$$\text{R}^{14}\text{CONH}-;$$

$$\text{R}^{13} \text{ is C1-C3-alkyl};$$

$$\text{R}^{14} \text{ is H or C1-C3-alkyl};$$

$$\text{R}^{15} \text{ and } \text{R}^{16} \text{ are independently}$$

$$\text{H},$$

$$\text{C1-C10-alkyl},$$

$$\text{C1-C6-perfluoroalkyl},$$

$$\text{C3-C10-alkenyl}, \text{ or}$$

$$\text{C3-C6-cycloalkyl}; \text{ or}$$

$$\text{R}^{15} \text{ and } \text{R}^{16} \text{ taken together can be C3-C6-cycloalkyl};$$

$$\text{R}^{17} \text{ is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl};$$

$$n \text{ is 1 to 6};$$

$$m \text{ is 0 to 2};$$

and pharmaceutically acceptable salts thereof;

wherein R^{10} and R^{11} cannot be both H.

2. The compound of claim 1 of Formula I wherein one of four substituents of R^1 , R^2 , R^3 and R^4 must be C1-C3-alkylthio group or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O$ -, $R^{13}S$ -, halogen (F, Cl, Br), or C1-C3-alkyl; R^2 and R^3 taken together can be $-SCH_2S$ -, $-SCH_2O$ -, or $-OCH_2S$ -; R^9 is

$R^{15}R^{16}NCO$ -,
 $R^{15}R^{16}NCS$ -,
 $R^{15}R^{16}N(CR^{17})$ -,
 $R^{17}OCO$ -,
 $R^{15}CO$ -, or
 H;

R^{10} and R^{11} are independently H, H_2N -, or CH_3CONH -; and pharmaceutically acceptable salts thereof.

3. The compound of claim 2 further comprising a pharmaceutically acceptable carrier.

4. The compound of claim 3 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α -amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

5. The compound of claim 2 of Formula I selected from the group consisting of

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-

methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-

amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine.


6. The compound of claim 5 further comprising a pharmaceutically acceptable carrier.

7. The compound of claim 6 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α -amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

8. The compound of claim 1 further comprising a pharmaceutically acceptable carrier.

9. The compound of claim 8 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α -amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

10. A method for treating a patient having a disorder associated with excessive activation of the α -amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors, the method comprising administering to the patient, in an effective amount to alleviate the symptoms of the disorder, a compound of Formula I:



wherein

R^1 , R^2 , R^3 and R^4 are independently

H,
 HO,
 $R^{13}O-$,
 halogen (F, Cl, Br),
 C1-C3-alkyl,
 CF_3 ,
 $R^{14}CO_2-$,
 $R^{14}O_2C-$,
 $R^{14}CO-$,
 $R^{14}CONH-$,
 $R^{14}NHCO-$,
 $R^{14}NHCO_2-$,
 $R^{14}OCONH-$,
 $R^{14}O_2S-$,
 $R^{14}OS-$, or

$R^{15}R^{16}N-$; or

R^1 and R^2 , or R^2 and R^3 , or R^3 and R^4 taken together can be

$-SCH_2S-$,

$-SCH_2O-$;

$-OCH_2S-$,

$-SCH_2CH_2S-$,

$-SCH_2CH_2O-$, or

$-OCH_2CH_2S-$;

wherein one of R^1 , R^2 , R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5 , R^6 , R^7 , and R^8 are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen (F, Cl, Br), $R^{13}O-$, CF_3- , $R^{14}O_2S-$, $R^{14}OS-$, $R^{14}CO$, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CONH-$, $R^{14}NHCO$; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^7 and R^8 taken together can be C3-C6-cycloalkyl;

R^9 is

$R^{15}R^{16}NCO-$,

$R^{15}R^{16}NCS-$,

$R^{15}R^{16}N(CR^{17})-$,

$R^{17}OCO-$,

$R^{15}CO-$,

$R^{15}R^{16}NCH_2CO-$,

$R^{14}O_2C-(CH_2)_n-$,

$R^{15}R^{16}NCO-(CH_2)_n-$,

$NC-(CH_2)_n-$,

H,

C1-C6-alkyl,
 C3-C6-alkenyl, or
 C3-C6-cycloalkyl; or

R^8 and R^9 taken together can be

$-(CH_2)_mCH_2(R^{15})NCO-$,
 $-(CH_2)_mCH_2OCO-$, or
 $-(CH_2)_mCH_2CH_2CO-$;

R^{10} and R^{11} are independently

H,
 $R^{15}R^{16}N-$,
 $R^{15}R^{16}N(CR^{17})-$,
 $R^{14}HNCO-$, or
 $R^{14}CONH-$;

R^{12} is

H,
 halogen (F, Cl, Br),
 HO,
 $R^{13}O-$,
 $R^{15}R^{16}N-$,
 C1-C3-alkyl,
 CF_3 ,
 $R^{14}CO_2-$,
 $R^{14}CO-$, or
 $R^{14}CONH-$;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,
 C1-C10-alkyl,
 C1-C6-perfluoroalkyl,
 C3-C10-alkenyl, or
 C3-C6-cycloalkyl; or

R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

R^{17} is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

n is 1 to 6;

m is 0 to 2;

and pharmaceutically acceptable salts thereof;

wherein R^{10} and R^{11} cannot be both H,

in combination with a pharmaceutically acceptable carrier.

11. The method of claim 10 wherein, in the compound of Formula I, one of four substituents of R^1 , R^2 , R^3 and R^4 must be C1-C3-alkylthio group or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O$ -, $R^{13}S$ -, halogen (F, Cl, Br), or C1-C3-alkyl;

R^2 and R^3 taken together can be $-SCH_2S$ -, $-SCH_2O$ -, or $-OCH_2S$ -;

R^9 is

$R^{15}R^{16}NCO$ -,

$R^{15}R^{16}NCS$ -,

$R^{15}R^{16}N(CR^{17})$ -,

$R^{17}OCO$ -,

$R^{15}CO$ -, or

H;

R^{10} and R^{11} are independently H, H_2N -, or CH_3CONH -; and pharmaceutically acceptable salts thereof.

12. The method of claim 11 wherein the disorder is selected from the group consisting of neurological, neuropsychological, neuropsychiatric, neurodegenerative, neuropsychopharmacological and functional disorders.

13. The method of claim 11 wherein the compound of Formula I is selected from the group consisting of

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-


benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-

ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine.

14. The method of claim 13 wherein the disorder is selected from the group consisting of neurological, neuropsychological, neuropsychiatric, neurodegenerative, neuropsychopharmacological and functional disorders.

15. The method of claim 10 wherein the disorder is selected from the group consisting of neurological, neuropsychological, neuropsychiatric, neurodegenerative, neuropsychopharmacological and functional disorders.

16. A compound of Formula II:



wherein

R^1 , R^2 , R^3 and R^4 are independently

H,

HO,

$R^{13}O-$,

halogen (F, Cl, Br),

C1-C3-alkyl,

CF_3 ,

$R^{14}CO_2-$,

$R^{14}O_2C-$,

$R^{14}CO-$,

$R^{14}CONH-$,

$R^{14}NHCO-$,

$R^{14}NHCO_2-$,

$R^{14}OCONH-$,

$R^{14}O_2S-$,

$R^{14}OS-$, or

$R^{15}R^{16}N-$; or

R^1 and R^2 , or R^2 and R^3 , or R^3 and R^4 taken together can be

$-SCH_2S-$,

$-SCH_2O-$,

$-OCH_2S-$,

$-SCH_2CH_2S-$,

$-SCH_2CH_2O-$, or

$-OCH_2CH_2S-$; or

one of four substituents of R^1 , R^2 , R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5 , R^6 , and R^7 are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl, or

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen (F, Cl, Br), $R^{13}O-$, CF_3- , $R^{14}O_2S-$, $R^{14}OS-$, $R^{14}CO$, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CONH-$, $R^{14}NHCO$; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

R^{17} is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

R^{18} and R^{19} are independently

H,

halogen (F, Cl, Br),

C1-C3-alkyl,

$R^{14}O-$,

CF_3- , or

$R^{14}CO_2-$;

R^{20} and R^{21} are independently

H,

$R^{15}R^{16}N-$,

$R^{15}HNC(NH)-$, or

$R^{14}CONH-$;

and pharmaceutically acceptable salts thereof;

wherein R^{20} and R^{21} cannot both be H.

17. The compound of claim 16 of Formula II wherein one of four substituents of R^1 , R^2 , R^3 and R^4 must be C1-C3-alkylthio or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O$ -, $R^{13}S$ -, halogen (F, Cl, Br), or C1-C3-alkyl; R^2 and R^3 taken together can be $-SCH_2S$ -, $-SCH_2O$ -, or $-OCH_2S$ -; R^{20} and R^{21} are independently H, H_2N -, or CH_3CONH -; and pharmaceutically acceptable salts thereof.

18. The compound of claim 17 further comprising a pharmaceutically acceptable carrier.

19. The compound of claim 18 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α -amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

20. The compound of claim 17 of Formula II selected from the group consisting of

1-(4-Aminophenyl)-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-4-methyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine.


21. The compound of claim 20 further comprising a pharmaceutically acceptable carrier.

22. The compound of claim 21 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α -amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

23. The compound of claim 16 further comprising a pharmaceutically acceptable carrier.

24. The compound of claim 23 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α -amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

25. A method for treating a patient having a disorder associated with excessive activation of the α -amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors, the method comprising administering to the patient, in an effective amount to alleviate the symptoms of the disorder, a compound of Formula II:



wherein

R^1 , R^2 , R^3 and R^4 are independently

H,

HO,

$R^{13}O-$,

halogen (F, Cl, Br),

C1-C3-alkyl,

CF_3 ,

$R^{14}CO_2-$,

$R^{14}O_2C-$,

$R^{14}CO-$,

$R^{14}CONH-$,

$R^{14}NHCO-$,
 $R^{14}NHCO_2-$,
 $R^{14}OCONH-$,
 $R^{14}O_2S-$,
 $R^{14}OS-$, or
 $R^{15}R^{16}N-$; or

R^1 and R^2 , or R^2 and R^3 , or R^3 and R^4 taken together can be

$-SCH_2S-$,
 $-SCH_2O-$,
 $-OCH_2S-$,
 $-SCH_2CH_2S-$,
 $-SCH_2CH_2O-$, or
 $-OCH_2CH_2S-$; or

one of four substituents of R^1 , R^2 , R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5 , R^6 , and R^7 are independently

H,
 C1-C6-alkyl,
 C3-C6-alkenyl,
 C3-C6-cycloalkyl, or

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen (F, Cl, Br), $R^{13}O-$, CF_3- , $R^{14}O_2S-$, $R^{14}OS-$, $R^{14}CO$, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CONH-$, $R^{14}NHCO$; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,
 C1-C10-alkyl,
 C1-C6-perfluoroalkyl,
 C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R¹⁵ and R¹⁶ taken together can be C3-C6-cycloalkyl;

R¹⁷ is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

R¹⁸ and R¹⁹ are independently

H,

halogen (F, Cl, Br),

C1-C3-alkyl,

R¹⁴O-,

CF₃-, or

R¹⁴CO₂-;

R²⁰ and R²¹ are independently

H,

R¹⁵R¹⁶N-,

R¹⁵HNC(NH)-, or

R¹⁴CONH-;

and pharmaceutically acceptable salts thereof;

wherein R²⁰ and R²¹ cannot both be H,

in combination with a pharmaceutically acceptable carrier.

26. The method of claim 25 wherein, in the compound of Formula II, one of four substituents of R¹, R², R³ and R⁴ must be C1-C3-alkylthio or C1-C3-alkoxy group, the other substituents are independently H, R¹³O-, R¹³S-, halogen (F, Cl, Br), or C1-C3-alkyl;

R² and R³ taken together can be -SCH₂S-, -SCH₂O-, or -OCH₂S-;

R²⁰ and R²¹ are independently H, H₂N-, or CH₃CONH-; and pharmaceutically acceptable salts thereof.

27. The method of claim 26 wherein the disorder is selected from the group consisting of neurological, neuropsychological, neuropsychiatric, neurodegenerative, neuropsychopharmacological and functional disorders.

28. The method of claim 26 wherein the compound of Formula II is selected from the group consisting of

1-(4-Aminophenyl)-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-

Aminophenyl)-4-methyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-4-methyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine.

29. The method of claim 28 wherein the disorder is selected from the group consisting of neurological, neuropsychological, neuropsychiatric, neurodegenerative, neuropsychopharmacological and functional disorders.

30. The method of claim 25 wherein the disorder is selected from the group consisting of neurological, neuropsychological, neuropsychiatric, neurodegenerative, neuropsychopharmacological and functional disorders.

Figure 1: 7- or 8- Mono substituted 5H-2,3-benzodiazepines

